Table 7.
Adverse events (>10%) during treatment with regorafenib after lenvatinib in patients with advanced HCC
| Events | Regorafenib (any lines) (n = 22) | Regorafenib (third line) (n = 17) | ||
|---|---|---|---|---|
| any (%) | grade ≥3 (%) | any (%) | grade ≥3 (%) | |
| Aspartate aminotransferase increased | 13 (59.1) | 2 (9.1) | 11 (64.7) | 2 (11.8) |
| Proteinuria | 12 (54.6) | 0 | 9 (52.9) | 0 |
| Hypertension | 10 (45.6) | 2 (9.1) | 9 (52.9) | 2 (11.8) |
| Fatigue | 9 (40.9) | 0 | 7 (41.2) | 0 |
| Palmar-plantar erythrodysesthesia | 8 (36.4) | 2 (9.1) | 4 (23.5) | 0 |
| Hypoalbuminemia | 8 (36.4) | 0 | 8 (47.1) | 0 |
| Anorexia | 7 (31.8) | 0 | 6 (35.3) | 0 |
| Bilirubin increased | 7 (31.8) | 3 (13.6) | 7 (41.2) | 3 (17.6) |
| Diarrhea | 6 (27.3) | 1 (4.5) | 4 (23.5) | 1 (5.9) |
| Hypothyroidism | 5 (22.7) | 0 | 4 (23.5) | 0 |
| Anemia | 5 (22.7) | 0 | 5 (29.4) | 0 |
| Thrombocytopenia | 5 (22.7) | 2 (9.1) | 5 (29.4) | 2 (11.8) |
| Serum amylase increased | 4 (18.2) | 0 | 3 (17.6) | 0 |
| Weight loss | 3 (13.6) | 0 | 3 (17.6) | 0 |
HCC, hepatocellular carcinoma.